N-[4-(methylsulfonylamino)benzyl]hydroxylamine | 681810-37-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-[4-(methylsulfonylamino)benzyl]hydroxylamine
• 英文别名: N-[4-[(hydroxyamino)methyl]phenyl]methanesulfonamide
• CAS: 681810-37-7
• 化学式: C₈H₁₂N₂O₃S
• 分子量: 216.261
• InChiKey: BPDOSWZJZXXJGH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.2
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  86.8
• 氢给体数：
  3
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  4-叔-丁基苄基异硫氰酸酯 、 N-[4-(methylsulfonylamino)benzyl]hydroxylamine 以 N,N-二甲基甲酰胺 为溶剂， 生成 JYL-1371
  参考文献：
  名称：

  Analysis of structure–activity relationships for the ‘B-region’ of N-(4-t-butylbenzyl)-N′-[4-(methylsulfonylamino)benzyl]-thiourea analogues as TRPV1 antagonists

  摘要：

  The structure-activity relationships for the 'B-region' of N-(4-t-butylbenzyl)-N '-[4-(methylsulfonylamino)benzyl]thiourea analogues have been investigated as TRPV1 receptor antagonists. A docking model of potent antagonist 2 with the sensor region of TRPV1 is proposed. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.06.006
• 作为产物：
  描述：

  在 吡啶 、 三氟乙酸 作用下， 生成 N-[4-(methylsulfonylamino)benzyl]hydroxylamine
  参考文献：
  名称：

  N-（3-酰氧基-2-苄基丙基）-N（'）-[4-（甲基磺酰基氨基）苄基]硫脲类似物作为类香草酸受体拮抗剂的“ B区”的结构活性关系分析：N的发现-羟基硫脲类似物，具有有效的镇痛作用。

  摘要：

  研究了强效和高亲和力类香草醇受体（VR1）铅配体N-（3-酰氧基-2-苄基丙基）-N（'）-[4-（甲基磺酰基氨基）苄基]硫脲在B区的结构修饰。用不同的等排官能团取代硫脲。结构活性分析表明，该系列中的A区是决定激动/拮抗活性的主要因素，而与B区无关。与母体硫脲类似物相比，N（C）-羟基硫脲类似物（12、13）在乙酸扭曲试验中显示出出色的镇痛活性。

  DOI：

  10.1016/j.bmcl.2004.02.002

文献信息

• [EN] NOVEL N-HYDROXY THIOUREA, UREA AND AMIDE COMPOUNDS AND THE PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME<br/>[FR] NOUVEAUX COMPOSES DE N-HYDROXYTHIOUREE, D'UREE ET AMIDES ET LES COMPOSITIONS PHARMACEUTIQUES LES RENFERMANT
  申请人：DIGITAL BIOTECH CO LTD

  公开号：WO2004035533A1

  公开（公告）日：2004-04-29

  The present invention relates to novel n-hydroxythiourea, urea and amide compounds as a potent vanilloid receptor antagonist and the pharmaceutical compositions comprising the same. The inventive compound can be useful for analgesics to prevent, alleviate or treat pain diseases or inflammatory disease comprising pain, acute pain, chronic pain, neuropathic pain, post-operative pain, migraine, arthralgia, neuropathies, nerve injury, diabetic neuropathy, neurodegeneration, neurotic skin disorder, stroke, urinary bladder hypersensitiveness, irritable bowel syndrome, a respiratory disorder such as asthma or chronic obstructive pulmonary disease, irritation of skin, eye or mucous membrane, fervescence, stomach-duodenal ulcer, inflammatory bowel disease, inflammatory disease and urgent urinary incontinence.

  本发明涉及新型n-羟基硫脲、尿素和酰胺化合物，作为有效的辣椒素受体拮抗剂，以及包含这些化合物的药物组合物。这种创新化合物可用于镇痛药，用于预防、缓解或治疗疼痛疾病或包括疼痛的炎症性疾病，如急性疼痛、慢性疼痛、神经痛、术后疼痛、偏头痛、关节痛、神经病、神经损伤、糖尿病性神经病、神经退行性疾病、神经性皮肤疾病、中风、尿道膀胱过敏、肠易激综合征、哮喘或慢性阻塞性肺疾病等呼吸道疾病、皮肤、眼睛或粘膜刺激、发热、胃十二指肠溃疡、炎症性肠病、炎症性疾病和急性尿失禁。
• Novel n-hydroxy thiourea, urea and amide compounds and the pharmaceutical compositions comprising the same
  申请人：Lee Jee-Woo

  公开号：US20050288369A1

  公开（公告）日：2005-12-29

  The present invention relates to novel n-hydroxythiourea, urea and amide compounds as a potent vanilloid receptor antagonist and the pharmaceutical compositions comprising the same. The inventive compound can be useful for analgesics to prevent, alleviate or treat pain diseases or inflammatory disease comprising pain, acute pain, chronic pain, neuropathic pain, post-operative pain, migraine, arthralgia, neuropathies, nerve injury, diabetic neuropathy, neurodegeneration, neurotic skin disorder, stroke, urinary bladder hypersensitiveness, irritable bowel syndrome, a respiratory disorder such as asthma or chronic obstructive pulmonary disease, irritation of skin, eye or mucous membrane, fervescence, stomach-duodenal ulcer, inflammatory bowel disease, inflammatory disease and urgent urinary incontinence.

  本发明涉及新型的N-羟基硫脲、尿素和酰胺化合物，作为有效的vanilloid受体拮抗剂及其药物组合物。该创新化合物可用作镇痛药，用于预防、缓解或治疗疼痛疾病或伴随疼痛的炎症性疾病，包括急性疼痛、慢性疼痛、神经病性疼痛、术后疼痛、偏头痛、关节痛、神经病、神经损伤、糖尿病神经病变、神经退行性疾病、神经性皮肤病、中风、膀胱过敏、肠易激综合征、哮喘或慢性阻塞性肺疾病、皮肤、眼睛或黏膜刺激、发热、胃十二指肠溃疡、炎症性肠病、炎症性疾病和紧急尿失禁。
• NOVEL N-HYDROXY THIOUREA, UREA AND AMIDE COMPOUNDS AND THE PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME
  申请人：Digital Biotech Co., Ltd.

  公开号：EP1558574A1

  公开（公告）日：2005-08-03
• EP1558574A4
  申请人：——

  公开号：EP1558574A4

  公开（公告）日：2006-06-21
• Analysis of structure–activity relationships for the ‘B-region’ of N-(4-t-butylbenzyl)-N′-[4-(methylsulfonylamino)benzyl]-thiourea analogues as TRPV1 antagonists
  作者：Jeewoo Lee、Mi-Kyoung Jin、Sang-Uk Kang、Su Yeon Kim、Jiyoun Lee、Myoungyoup Shin、Jaemin Hwang、Sookhyun Cho、Yeon-Sil Choi、Hyun-Kyung Choi、Sung-Eun Kim、Young-Ger Suh、Yong-Sil Lee、Young-Ho Kim、Hee-Jin Ha、Attila Toth、Larry V. Pearce、Richard Tran、Tamas Szabo、Jacqueline D. Welter、Daniel J. Lundberg、Yun Wang、Jozsef Lazar、Vladimir A. Pavlyukovets、Matthew A. Morgan、Peter M. Blumberg

  DOI：10.1016/j.bmcl.2005.06.006

  日期：2005.9

  The structure-activity relationships for the 'B-region' of N-(4-t-butylbenzyl)-N '-[4-(methylsulfonylamino)benzyl]thiourea analogues have been investigated as TRPV1 receptor antagonists. A docking model of potent antagonist 2 with the sensor region of TRPV1 is proposed. (c) 2005 Elsevier Ltd. All rights reserved.